In all biological products, distinguishing aggregated API from other particle types matters for understanding the root cause of instability. Until now, subvisible particle or biophysical characterization methods have been unreliable, slow, require significant sample volume, and have been difficult to use across different therapeutics. Here we present Aura®+, a USP 1788 compatible, low-volume, high throughput particle imaging system that can rapidly size, count, and characterize biological particles and identify them as proteins, non-proteins, cellular aggregates, or other types of molecules. In this webinar, we discuss how to characterize for product stability, purity, and other critical quality attributes in the pre-clinical stages ensuring the development of effective and safe drugs.
About the speaker
Dikran Khachadourian is a Field Application Scientist at Halo Labs. Dikran completed his undergraduate studies at UC San Diego, obtaining a bachelor's degree in Biochemistry and Cell Biology. His interest in the biological sciences led him to pursue a master's degree in Biology. After spending time in academia as a graduate researcher and educator, Dikran joined the Halo Labs team to apply his background to the ongoing advancements in biotechnology.